Attralus Therapeutics welcomes Mark Timney as CEO and appoints Dr. Rahul Kakkar to its Board as Independent Director

– USA, CA –  Attralus Therapeutics today announced the appointment of Mark Timney to its Board of Directors as the CEO, bringing more than 30 years of leadership experience at publicly traded and global biopharmaceutical companies.

“We are pleased to welcome Mark Timney as CEO of Attralus, as he brings a track record for delivering value for patients, health care systems and investors. His leadership will guide Attralus to realize the potential of its transformative therapies for systemic amyloidosis which address a wide range of unmet needs for patients with all forms of this disease,” said Dr. Richard Gaster, Attralus Board member and Partner at venBio Partners.

The company also expanded the Board of Directors with the appointment of Dr. Rahul Kakkar, MD as an independent director who brings 20 years of experience founding and building biotechnology companies and as a practicing physician.

In addition, the company announced the appointment of four additional executives to its leadership team bringing each more than 20 years of experience in the biopharmaceutical industry in their respective areas of expertise:

  • Dr. Gregory Bell, MD, Chief Medical Officer;
  • Glen Firestone, Chief Business Officer;
  • Dr. Krishna Gorti, MD, Head of Corporate Development;
  • Dr. Michael Klein, Ph.D., Head of Chemistry, Manufacturing, and Controls.

About Mark Timney

Mark Timney in his most recent role was CEO of The Medicines Company (NASDAQ: MDCO) until its sale for $9.7 billion to Novartis AG (NYSE: NVS) which was completed in 2020. He joins Attralus to accelerate the clinical development of its product pipeline and expand the company’s business plan. Spencer Guthrie, the co-founder who led the company during early development, will continue at Attralus as Chief Operating Officer.

Mark Timney said, “I am excited to lead Attralus, a company built on deep fundamental research in the field of amyloidosis with a strong commitment to delivering life-changing therapies for patients. I see an extraordinary opportunity for Attralus to advance novel pan-amyloid removal therapies that open the potential to treat and reverse disease in patients with all types of systemic amyloidosis. There are extensive, unmet medical needs that can be addressed by diagnosing and therapeutically removing toxic, disease-causing amyloid in patients with systemic amyloidosis. I look forward to working with the very talented team at Attralus to make a significant difference in the lives of these patients.”

In leadership roles at publicly traded and global biopharmaceutical companies, Timney has successfully managed companies through stages of growth and transition, launched numerous breakthrough medicines, and led high-value strategic transactions. Most recently, Timney served as CEO and Board member of The Medicines Company where he led the company through late-stage clinical development and maximized the potential for inclisiran, a first-in-class siRNA cholesterol-lowering therapy. These actions increased shareholder return more than three-fold within one year and culminated in the company’s acquisition by Novartis. Previously, he held senior roles in biopharmaceutical companies that include Merck & Co., Purdue Pharmaceuticals, Zeneca Group, ICI Pharmaceuticals, and Roussel Labs, and has led markets that include the United States, Japan, South Korea, Australia, and New Zealand.

He received a bachelor’s degree from Newcastle Polytechnic (now Northumbria University) in Newcastle in the United Kingdom.

About Dr. Rahul Kakkar

Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience, spanning founding and building biotechnology companies, as well as working as a practicing physician. Most recently, he was CEO at Pandion Therapeutics, a company developing innovative modular therapeutics for autoimmune and inflammatory diseases, which he led to reach the stage as a clinical-stage company and completed an initial public offering before Pandion’s acquisition by Merck for $1.9 billion. Before joining Pandion, he served as an executive at Corvidia Therapeutics where he was a founder, Chief Medical Officer, and Chief Strategy Officer, guiding the company from seed stage through Series B and its lead asset through clinical proof of concept. Corvidia was acquired by Novo Nordisk for $2.1 billion. Corvidia was a “spin-out” from AstraZeneca, where Dr. Kakkar had served as Director for Emerging Innovations, responsible for preclinical through Phase 2 clinical studies both for compounds within the AstraZeneca pipeline and in support of compound out-licensing efforts. He continues to practice medicine as an Associate Physician at Brigham and Woman’s Hospital and is a Lecturer in Medicine at Harvard Medical School.

Dr. Kakkar is dual-trained via the American Board of Internal Medicine Fast Track program in molecular biology and clinical cardiology, and he is a fellow of the American College of Cardiology.

About Attralus

Attralus is a clinical-stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. The company’s proprietary pan-amyloid removal therapeutic product candidates are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis. Attralus was founded by scientific experts in the field of amyloidosis and is headquartered in South San Francisco, California.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.